Universe Pharmaceuticals Shares Jump 288% After $10.75M Patent Acquisition
UPC•Universe Pharmaceuticals agreed to acquire five Chinese pharmaceutical patents from Best Praise International for $10.75 million in Class A shares, broadening its IP in elderly healthcare, neurodegenerative and cardiovascular treatments. The board-approved transaction, set to close in Q3 2026, triggered a 288% after-hours share rally.
1. Acquisition Terms
Universe Pharmaceuticals agreed to purchase 100% of Best Praise International Limited, gaining five Chinese patents covering age-related diseases, neurodegenerative and cardiovascular treatments. The $10.75 million deal will be paid in Class A shares and has received board approval.
2. Strategic Rationale
The patents expand the firm’s intellectual property in elderly healthcare, cognitive disorders, antibacterial compounds and drug delivery technologies, supporting product pipeline diversification and long-term growth in traditional Chinese medicine offerings.
3. Market Reaction
Following the announcement, shares jumped 288% in after-hours trading. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.
